Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media › C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210)
12/2003
12/04/2003US20030224412 Structurally biased random peptide libraries based on different scaffolds
12/04/2003US20030224410 Selecting nucleic acid sequences coding ligand and receptor molecules capable of specific binding to each other for use in epitope mapping; rational drug design
12/04/2003US20030224408 Ligand screening and discovery
12/04/2003US20030224404 Optimizing the activity of proteins, nucleic acids and peptides by means of random changes introduced into selected preferential genes; mutational analysis
12/04/2003US20030224402 Progression suppressed gene 13 (PSGen 13) and uses thereof
12/04/2003US20030224396 Regulation of human aminotransferase-like enzyme
12/04/2003US20030224394 Computer systems and methods for identifying genes and determining pathways associated with traits
12/04/2003US20030224390 Screening combinatorial peptide libraries for identifing amino acid sequences which bind and activate cellular processes; drug screening
12/04/2003US20030224389 Concurrently separating double and single stranded polynucleotide sequences present in mixture via absorption of nucleic acids to mineral support; in vitro transcription
12/04/2003US20030224382 Measuring concentration of two or more nucleic acid molecules in target cell for use in diagnosing and treating cancer, autoimmune, infectious, aging, developmental, proliferative and neurological disorders
12/04/2003US20030224381 Delta-erythroid kruppel-like factors and methods of use
12/04/2003US20030224377 Novel LNA compositions and uses thereof
12/04/2003US20030224374 Classifying/diagnosing/prognosing tumorous condition via presence of estrogen receptor
12/04/2003US20030224369 Reverse screening and target identification with minicells
12/04/2003US20030224368 Crystallizable compositions comprising a caspase-7
12/04/2003US20030224366 Spherical glass surface composed of magnetic particles for the purification of biological materials; immunoassay; affinity chromatography
12/04/2003US20030224365 Single nucleotide polymorphisms diagnostic for schizophrenia
12/04/2003US20030224364 Compositions and methods for identifying and distinguishing orthosomycin biosynthetic loci
12/04/2003US20030224362 Diagnosing alcoholism using presence of mutation in neuropeptide y gene; drug abuse; restriction fragment length polymorphisms; immunoassay
12/04/2003US20030224361 Method of making random array of microspheres using enzyme digestion
12/04/2003US20030224360 Interventions to mimic the effects of calorie restriction
12/04/2003US20030224358 Comprises nucleotide sequences coding membrane protein for use as anticarcinogenic/antitumor/antiinflammatory agent
12/04/2003US20030224355 Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (alpha), HNF-1beta and HNF-4alpha
12/04/2003US20030224354 Quantifying viral particles with intrinsic fluorescence
12/04/2003US20030224353 Uncharged oligomers having a targeting base sequence that is substantially complementary to a viral target sequence which spans the AUG start site of the first open reading frame of the viral genome
12/04/2003US20030224350 Elimination of endogenous porcine retrovirus
12/04/2003US20030224345 Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
12/04/2003US20030224344 Method and system for clustering data
12/04/2003US20030224055 Compositions and processes for inhibiting gene expression using polynucleotides
12/04/2003US20030224040 Genomic screen for epigenetically silenced genes associated with cancer
12/04/2003US20030224018 Modified Vaccinia Virus Ankara for the vaccination of neonates
12/04/2003US20030224017 Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
12/04/2003US20030224016 Transport peptides such as C-terminal Erns peptide and analogues thereof
12/04/2003US20030224015 Administering to a mammal an immunogenic formulation containing an Ebola peptide, to induce a protective cytotoxic T lymphocyte response
12/04/2003US20030224012 Identifying a BASB033 polypeptide or an antibody that is immunospecific for such polypeptide, present with in a biological sample form the animal suspected having meningococcus induced infections and meningitis
12/04/2003US20030224009 An expression vector containing a promoter co-dependently regulatable by cyclic AMP and anaerobiosis, capable of at least one: being chromosomally integrated in bacterial cell, and being maintained extrachromosomally in a bacterial cell
12/04/2003US20030224007 A protective protein in the form of vaccine, containing a polypeptide from a pro-region of a cathepsin L protease obtained from excretory/secretory products of newly excysted juvenile stages of Fasciola hepatical
12/04/2003US20030224004 Chlamydia antigens and corresponding DNA fragments and uses thereof
12/04/2003US20030224000 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
12/04/2003US20030223994 Protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the
12/04/2003US20030223993 Novel steroid-activated nuclear receptors and uses therefor
12/04/2003US20030223992 G-protein coupled receptor ligands and methods
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223990 A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. 193P1E1 provides
12/04/2003US20030223987 Immunodeficiency recombinant poxvirus
12/04/2003US20030223986 Methods
12/04/2003US20030223977 Novel small proteins which bind cathepsin G have been identified. These are useful as inhibitors of excessive cathepsin G activity in patients.
12/04/2003US20030223976 Control sequences of the human corin gene
12/04/2003US20030223975 Based on the discovery that a Y-box protein binding site is present as a transcription enhancer sequence in the promoter region situated upstream (i.e., 5' to) of the human PTP1B gene. This site, situated at nucleotides -155 through -132 of
12/04/2003US20030223972 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
12/04/2003US20030223971 Gene therapy for the treatment of solid tumors using recombinant adeno-associated virus vectors
12/04/2003US20030223966 Treatment for pompe disease
12/04/2003US20030223964 Efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the
12/04/2003US20030223963 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/04/2003US20030223961 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
12/04/2003US20030223911 Identically shaped spots can be formed sequentially and stably by a spotting pin comprising a bar-like plunger 20. Four projections each formed in the shape of a top portion of a quadrangular pyramid are formed on the head of the plunger
12/04/2003CA2704273A1 Mn/ca ix-antibody binding specifically to non-immunodominant epitope of mn/ca ix and uses thereof
12/04/2003CA2694419A1 Isolated polynucleotides and methods of promoting a morphology in a fungus
12/04/2003CA2525976A1 Modulation of ptp1b signal transduction by rna interference
12/04/2003CA2505598A1 A bank of stem cells for transplantation
12/04/2003CA2505592A1 Generation of histocompatible tissues using nuclear transplantation
12/04/2003CA2497091A1 Adiponectin-knoucout nonhuman animal
12/04/2003CA2493902A1 Decoy composition for treating and preventing inflammatory disease
12/04/2003CA2489145A1 Insulin-sensitizing agent
12/04/2003CA2487811A1 Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487452A1 A method for generating antigen-presenting cells
12/04/2003CA2487322A1 Animal genotyping method
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487283A1 Method for assembling sub units into capsoides
12/04/2003CA2487243A1 Transformed fungi for production of recombinant proteins
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487112A1 Neuregulin based methods and compositions for treating cardiovascular diseases
12/04/2003CA2487106A1 Protein c polymorphisms
12/04/2003CA2487093A1 Microarrays and method for running hybridization reaction for multiple samples on a single microarray
12/04/2003CA2487040A1 A repressor-mediated regulation system for control of gene expression in plants
12/04/2003CA2486967A1 Cardiolipin compositions their methods of preparation and use
12/04/2003CA2486918A1 Novel chimeric cd154
12/04/2003CA2486578A1 Detection of secreted polypeptides
12/04/2003CA2486559A1 Fatty acid desaturases from fungi
12/04/2003CA2486431A1 Computer systems and methods for subdividing a complex disease into component diseases
12/04/2003CA2486408A1 Methods and compositions for regulation and manipulation of steroidogenesis
12/04/2003CA2486218A1 Method for identifying type-i interferon responsive ms patients by determining trail expression
12/04/2003CA2485837A1 Methods and dna constructs for high yield production of polypeptides
12/04/2003CA2485835A1 Methods and dna constructs for high yield production of polypeptides
12/04/2003CA2485829A1 Methods and constructs for high yield expression of clostripain
12/04/2003CA2485816A1 Vaccines
12/04/2003CA2485737A1 Polypeptide cleavage process
12/04/2003CA2485733A1 Vaccines
12/04/2003CA2485732A1 Generation and selection of protein library in silico
12/04/2003CA2485648A1 Claudin polypeptides, polynucleotides, and methods of making and use thereof
12/04/2003CA2485218A1 Method for creating polynucleotide molecules
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2484000A1 Neutralizing human anti-igfr antibody
12/04/2003CA2483201A1 Murine ortholog of the human disrupted-in-schizophrenia 1 gene
12/04/2003CA2480548A1 Compositions and methods of use for a bombesin peptide
12/04/2003CA2478833A1 Anti-.alpha.v.beta.6 antibodies
12/03/2003EP1367138A2 Markers for breast cancer prognosis
12/03/2003EP1367137A1 Methods of isolating biological target materials using silica magnetic particles
1 ... 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 ... 4023